EUR 3.08
(-1.6%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 2.89 Million EUR | -18.49% |
2022 | 3.54 Million EUR | 278.44% |
2021 | 938.01 Thousand EUR | 272.23% |
2020 | 252 Thousand EUR | 0.0% |
2019 | - EUR | 0.0% |
2018 | - EUR | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 FY | 2.89 Million EUR | -18.49% |
2023 Q2 | - EUR | -100.0% |
2022 Q4 | 3.54 Million EUR | 0.0% |
2022 Q2 | - EUR | -100.0% |
2022 FY | 3.54 Million EUR | 278.44% |
2021 Q4 | 938.01 Thousand EUR | 0.0% |
2021 FY | 938.01 Thousand EUR | 272.23% |
2021 Q2 | - EUR | -100.0% |
2020 Q2 | - EUR | 0.0% |
2020 Q4 | 252 Thousand EUR | 0.0% |
2020 FY | 252 Thousand EUR | 0.0% |
2019 FY | - EUR | 0.0% |
2018 FY | - EUR | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
MPH Health Care AG | 8.33 Million EUR | 65.279% |
Apontis Pharma AG | 6 Million EUR | 51.776% |
Dermapharm Holding SE | 950.7 Million EUR | 99.696% |
Evotec SE | 477.11 Million EUR | 99.394% |
MERCK Kommanditgesellschaft auf Aktien | 8.84 Billion EUR | 99.967% |
PharmaSGP Holding SE | 65.37 Million EUR | 95.574% |